Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial

Sheppard JP. et al, (2024), The Lancet Healthy Longevity, 5, e563 - e573

Validation of an acute respiratory infection phenotyping algorithm to support robust computerised medical record-based respiratory sentinel surveillance, England, 2023.

Elson WH. et al, (2024), Euro Surveill, 29

Effect of antihypertensive deprescribing on serious adverse events, mortality, and cardiovascular disease: Long-term follow-up of the OPTiMISE randomised controlled trial

SHEPPARD J. et al, (2024), The Lancet Healthy Longevity

Reliability of single-lead electrocardiogram interpretation to detect atrial 1 fibrillation: insights from the SAFER Feasibility Study

MCMANUS R. and HOBBS R., (2024), Europace

A Profile of Influenza Vaccine Coverage for 2019-2020: Database Study of the English Primary Care Sentinel Cohort

Hoang U. et al, (2024), JMIR public health and surveillance, 10

EFFECT OF ANTIHYPERTENSIVE DEPRESCRIBING ON SERIOUS ADVERSE EVENTS, MORTALITY, AND CARDIOVASCULAR DISEASE: LONG-TERM FOLLOW-UP OF THE OPTIMISE RANDOMISED CONTROLLED TRIAL

Sheppard J. et al, (2024), Journal of Hypertension, 42, e109 - e110

The Association between Blood Test Trends and Undiagnosed Cancer: A Systematic Review and Critical Appraisal

Virdee PS. et al, (2024), Cancers, 16

Randomised controlled trial of population screening for atrial fibrillation in people aged 70 years and over to reduce stroke: protocol for the SAFER trial

Mant J. et al, (2024), BMJ Open, 14

Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study

Tsang RSM. et al, (2024), Journal of the Royal Society of Medicine, 117, 134 - 148

AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: The RAVEN cohort study

Meeraus W. et al, (2024), Journal of Infection, 88

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Hayward G. et al, (2024), Journal of Infection, 88

Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized Trials.

Shah SJ. et al, (2024), Circ Cardiovasc Qual Outcomes

Diagnostic accuracy of a point-of-care antigen test for SARS-CoV-2 and influenza in a primary care population (RAPTOR-C19)

Fanshawe TR. et al, (2024), Clinical Microbiology and Infection, 30, 380 - 386

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.

Hobbs FDR. et al, (2024), Infect Dis Ther, 13, 521 - 533

The feasibility of population screening for paroxysmal atrial fibrillation using handheld ECGs.

Mant J. et al, (2024), Europace

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Standing JF. et al, (2024), Nature communications, 15

Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales

Bedston S. et al, (2024), The Lancet Regional Health - Europe, 37

Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic Review and Meta-analysis for Enhanced Disease Surveillance.

Leston M. et al, (2024), J Infect

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.

Png ME. et al, (2024), Br J Gen Pract

An eDElphi STudy to defINe and risk-stratify ImmunosupprESsion: Protocol for the DESTINIES Study (Preprint)

Leston M. et al, (2024), JMIR Research Protocols

Load More

1
2
3
4
5
6
7
...
»